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Abstract
To extend understanding of the genetic architecture and molecular basis of type 2 diabetes (T2D),
we conducted a meta-analysis of genetic variants on the Metabochip involving 34,840 cases and
114,981 controls, overwhelmingly of European descent. We identified ten previously unreported
T2D susceptibility loci, including two demonstrating sex-differentiated association. Genome-wide
analyses of these data are consistent with a long tail of further common variant loci explaining
much of the variation in susceptibility to T2D. Exploration of the enlarged set of susceptibility loci
implicates several processes, including CREBBP-related transcription, adipocytokine signalling
and cell cycle regulation, in diabetes pathogenesis.
Type 2 diabetes (T2D) is a chronic metabolic disease with multifactorial pathogenesis1.
Although the genetic contribution to T2D is well recognized, the current set of 56
established susceptibility loci, identified primarily through large-scale genome-wide
association studies (GWAS)2-11, captures at best 10% of familial aggregation of the disease.
The characteristics (effect sizes and risk allele frequencies (RAF)) of the variants
contributing to the “unexplained” genetic variance remain far from clear. At the same time,
difficulties in inferring biological mechanisms from the variants of modest effect identified
by GWAS have inhibited progress in defining the pathophysiological basis of disease
susceptibility. One key question is whether characterization of increasing numbers of risk
loci will provide evidence, at the functional level, that susceptibility involves a limited set of
molecular processes.
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To extend the discovery and characterization of variants influencing T2D susceptibility, we
performed large-scale genotyping using the Metabochip. This custom array of 196,725
variants was designed to facilitate cost-effective follow-up of nominal associations for T2D
and other metabolic and cardiovascular traits, and to enhance fine-mapping of established
loci12. The T2D-nominated component of Metabochip comprises 21,774 variants, including
5,057 “replication” SNPs that capture the strongest, independent (CEU r2 < 0.2) autosomal
association signals from the GWAS meta-analysis conducted by the DIAbetes Genetics
Replication and Meta-analysis (DIAGRAM) Consortium. This genome-wide meta-analysis
(“DIAGRAMv3”) includes data from 12,171 cases and 56,862 controls of European descent
imputed up to 2.5 million autosomal SNPs, and augments the previously published
“DIAGRAMv2” meta-analysis4 with four additional GWAS (Supplementary Table 1). The
T2D-nominated content of Metabochip includes a further 16,717 variants, most chosen from
1000 Genomes Project pilot data13, to fine-map 27 established susceptibility loci.
RESULTS
Study overview
Our primary investigation combined the DIAGRAMv3 (“Stage 1”) GWAS meta-analysis
with a “Stage 2” meta-analysis comprising 22,669 cases and 58,119 controls genotyped with
Metabochip, including 1,178 cases and 2,472 controls of Pakistani descent (PROMIS)
(Online Methods and Supplementary Table 1). There was little evidence of heterogeneity in
allelic effects between European- and Pakistani-descent studies in Stage 2 (Supplementary
Fig. 1), so we report the combined meta-analysis including PROMIS with genomic control
correction.
T2D susceptibility loci reaching genome-wide significance
Combining Stage 1 and Stage 2 meta-analyses (Supplementary Fig. 2), we identified eight
new T2D susceptibility loci at genome-wide significance (P < 5 × 10−8) (Table 1,
Supplementary Fig. 3 and Supplementary Table 2). By convention, we have labelled loci
according to the gene nearest to the lead SNP, unless a compelling biological candidate
maps nearby. The strongest signals mapped to ZMIZ1 (P = 1.0 × 10−10), ANK1 (P = 2.5 ×
10−10), and the region flanking KLHDC5 (P = 6.1 × 10−10). We also observed genome-wide
significant association at HMG20A (P = 4.6 × 10−9) and GRB14 (P = 1.0 × 10−8), both
implicated in a recent meta-analysis of T2D in South Asians10. Neither has previously been
reported in European studies, and both remain genome-wide significant after removing
PROMIS from the meta-analysis (HMG20A P = 1.9 × 10−9; GRB14 P = 5.8 × 10−9). The
lead SNPs from both meta-analyses are in strong linkage disequilibrium (LD) (HMG20A r2
= 0.89 and GRB14 r2 = 0.77 in CEU), and likely represent the same association signals. At
the previously unreported loci, we observed nominal evidence of association (P < 0.05) in
the South Asian10 and recent East Asian11 meta-analyses for the lead SNPs at MC4R and
ZMIZ1 (Supplementary Table 3), with consistent directions of effect across all three
ancestry groups.
Several of these signals map to loci previously implicated in T2D-related metabolic traits
(Supplementary Table 4). The lead SNP at MC4R is in strong LD with variants associated
with BMI14,15 (CEU r2 = 0.80) and triglycerides16 (CEU r2 = 0.84) and is associated with
waist circumference and insulin resistance17. As with FTO, the T2D-effect at MC4R is
probably secondary to the BMI association. The lead SNP at GRB14 is highly correlated
with variants associated with waist-hip ratio (WHR)18 and high-density lipoprotein (HDL)
cholesterol16 (CEU r2 = 0.93). At CILP2, the lead SNP for T2D is also associated with
triglycerides, low-density lipoprotein (LDL) and total cholesterol16. In contrast, the
previously-reported association signals for haemoglobin A1C (HbA1C) levels19 near ANK1
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are both independent (CEU r2 < 0.01) of the lead T2D SNP from our meta-analysis. Given
the role played by rare ANK1 mutations in hereditary anemias, the HbA1C associations at
this locus were assumed to be driven by abnormal erythrocyte development and/or function.
However, our newly discovered independent association with T2D (in cohorts where HbA1C
was not used for diagnosis) suggests that variation at this locus also has direct effects on
glucose homeostasis.
Insights into the genetic architecture of T2D
The associated lead variants at the eight newly identified loci were common (Stage 2 RAF
0.08-0.89) and had modest effects on T2D susceptibility (allelic odds ratios (OR) 1.07-1.14).
Under a multiplicative model within and between variants, the sibling relative risk
attributable to lead SNPs rose from λS = 1.093 at the 55 previously described autosomal
T2D loci represented on Metabochip (DUSP9 on chromosome X is not captured) to λS =
1.104 after inclusion of the eight newly discovered loci (Supplementary Table 5). Assuming
a T2D population prevalence of 8%, these 63 newly discovered and established autosomal
loci together account for 5.7% of variance in disease susceptibility, as calculated by
transforming dichotomous disease risk onto a continuous liability scale20 (Online Methods).
To determine the extent to which additional common variant associations contribute to the
overall variance explained, we compared directional consistency in allelic effects between
the two stages of the meta-analysis. Figure 1 presents the distribution of Z-scores from Stage
2, aligned to the risk allele from Stage 1, at a subset of 3,412 independent (CEU r2 < 0.05)
T2D replication variants that excludes lead SNPs and possible proxies (CEU r2 ≥ 0.1) at the
63 newly discovered and established loci represented on Metabochip. The blue curve
represents the expected distribution of Stage 2 Z-scores under the null hypothesis of no
association. There is a clear shift in the observed distribution, corresponding to closer
agreement in the direction of allelic effect than expected by chance: 2,172 (69.1%) of the
3,412 SNPs are concordant (binomial test P = 2.0 × 10−104). For comparison, we examined
T2D association patterns in 2,707 independent replication SNPs for QT-interval, the trait
showing weakest correlation with T2D susceptibility among those contributing to
Metabochip and found far less directional consistency (54.4%, binomial test P = 3.3 × 10−6).
This modest enrichment most likely reflects weak overlap of risk alleles between the two
traits, since exclusion of SNPs mapping within 300 kb of directionally consistent T2D
replication variants reduced this excess (52.5%, binomial test P = 0.060).
The observed distribution of Z-scores can be considered a mixture of: (i) the “null
distribution” of SNPs having no effect on T2D; and (ii) the “alternative distribution” of
T2D-associated SNPs (Online Methods). We estimated the features of this alternative
distribution (red curve) and noted that addition of this class of SNPs significantly improved
the fit to the observed Z-scores over the null model. Using simulations, based on parameter
estimates from this mixture model, we estimated that 488 (95% confidence interval (CI)
456-521) of the independent replication SNPs, in addition to the 63 newly discovered and
established loci, are associated with T2D susceptibility. For comparison, we undertook
false-discovery rate (FDR) analysis of the 64,646 SNPs on the Metabochip selected for
replication of any trait, using P-values from the combined meta-analysis (Online Methods).
We observed broad agreement between combined meta-analysis P-values, FDR Q-values
and the posterior probability of alternative distribution membership from the mixture model
(Supplementary Fig. 4).
We were concerned that these additional, weaker association signals might reflect subtle
stratification effects not eliminated by genomic control correction. However, using diverse
European populations from the 1000 Genomes Project13 (Online Methods), we found no
Morris et al. Page 7
Nat Genet. Author manuscript; available in PMC 2013 February 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
evidence that directionally-consistent T2D replication SNPs differed from other Metabochip
replication SNPs with respect to FST (P = 0.88).
As expected, the estimated allelic ORs of the 488 SNPs are modest (1.01-1.11 in Stage 2),
and larger samples would be required to establish association at genome-wide significance.
For example, by simulating an additional 100,000 T2D cases and 100,000 controls as a
“third stage” to the combined meta-analysis, we calculate that only ~37% of the 488
replication SNPs in the alternative distribution would achieve this threshold. We estimate
that these variants jointly account for λS = 1.088 (95% CI 1.083-1.094), increasing the
overall liability-scale variance explained to 10.7% (10.4-11.0%).
Additional sources of variation contributing to susceptibility
These estimates likely set a lower bound to the overall liability-scale variance attributable to
common SNPs. The mixture model does not take account loci not represented by
Metabochip T2D replication SNPs due to failures in array design or manufacture or because
the association signal in DIAGRAMv3 was too weak to merit inclusion. Indeed, the latter
applied to two of the genome-wide significant loci, ANKRD55 and GRB14, which were
nominated for inclusion on Metabochip because of associations with WHR (ANKRD55 and
GRB14), blood pressure (ANKRD55) and plasma lipid concentrations (GRB14), rather than
T2D.
To estimate the contribution to the variance explained by common variants genome-wide,
we undertook polygenic mixed linear modelling analyses using GCTA21,22 in two
DIAGRAMv3 GWAS data sets: DGI (1,022 cases, 1,075 controls) and WTCCC (1,924
cases, 2,938 controls). The estimated liability-scale variance explained by the full set of
GWAS SNPs was consistent between the two studies: 62.6% for DGI (95% CI 38.1-87.1%)
and 63.9% for WTCCC (95% CI 52.1-75.8%). These results are similar to those obtained
from a complementary method integrating polygenic risk score analysis and approximate
Bayesian computation23 applied to the DIAGRAMv2 meta-analysis4, which estimated that
~49% of liability-scale variance was explained by common variants genome-wide. These
data indicate that a substantial proportion of the variation in T2D risk is captured by
common variant association signals that, individually, lie beyond unequivocal detection in
single SNP analyses.
The DIAGRAMv2 meta-analysis4 had provided some evidence for loci harboring multiple
independent association signals. To understand the extent to which additional variance
might be attributable to multiple variants at established and newly discovered loci, we
extended these analyses, focusing on the detection of independent (CEU r2 < 0.05)
association signals that lie outside the recombination interval containing the lead SNP
(Supplementary Table 2). We detected two loci at which multiple independent association
signals attained genome-wide significance: KCNQ1 (rs163184, P = 1.2 × 10−11; rs231361, P
= 1.2 × 10−9; CEU r2 = 0.01) and CDKN2A/B (rs10811661, P = 3.7 × 10−27; rs944801, P =
2.4 × 10−9; CEU r2 = 0.01) (Fig. 2). Both signals at KCNQ1 have previously been reported
in East Asian and European populations4,24. However, the secondary signal at CDKN2A/B,
which maps to the non-coding CDKN2B-AS1 (ANRIL) transcript, has not previously been
implicated in T2D susceptibility. This signal is independent of the previously reported
haplotype effect at the primary T2D signal at this locus, which is itself likely due to the
phase relationships between two clades of partially correlated variants25,26. We also
observed putative independent associations (P < 10−5) at DGKB (rs17168486, P = 5.9 ×
10−11; rs6960043, P = 3.4 × 10−7; CEU r2 = 0.01) and MC4R (rs12970134, P = 1.2 × 10−8;
rs11873305, P = 3.8 × 10−7; CEU r2 = 0.02). These results suggest that multiple independent
association signals are widespread at T2D susceptibility loci. Imputation up to the more
complete reference panels emerging from the 1000 Genomes Project13 and recently
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developed approaches that support approximate conditional analyses using meta-analysis
summary level data27 will be important tools for documenting the full extent of such effects,
especially where the variants map to the same recombination interval.
It has been argued that common variant association signals will often reflect unobserved
causal alleles of lower frequency and greater effect size28. The fine-mapping content of
Metabochip allowed us to seek empirical evidence to support this “synthetic association”
hypothesis. We estimate, using 1000 Genomes Project data13 applied to HapMap CEU
samples, that the array captures (CEU r2 ≥ 0.8) 89.6% of common SNPs (minor allele
frequency (MAF) ≥ 5%) and 60.0% of low-frequency variants (1% ≤ MAF < 5%) across
Metabochip fine-mapping regions12. This represents a substantial improvement over
HapMap29,30 which, across the same regions, captures 76.8% and 32.4% of common and
low-frequency variants, respectively.
Across 36 fine-mapping regions on Metabochip that contain T2D susceptibility loci
(including 27 explicitly chosen by DIAGRAM), we compared the characteristics of
previously reported lead SNPs (defined by GWAS and HapMap imputation) and those
emerging from the Stage 2 Metabochip meta-analysis. We restricted these comparisons to
Stage 2 to avoid penalizing low-frequency variants not typed or well-imputed in Stage 1.
The GWAS and Metabochip lead SNPs were the same, or highly-correlated (CEU r2 > 0.8),
at 20 loci (15 with CEU r2 > 0.95) (Supplementary Table 6). The low LD between GWAS
and Metabochip lead SNPs at DGKB and KCNQ1 (both CEU r2 = 0.00) arises because they
“switch” between independent association signals at these loci (Fig. 2). For the remaining 14
loci, there was only modest LD between the previously reported GWAS and Metabochip-
defined lead SNPs (CEU r2 between 0.06 and 0.77). However, at only two loci did the lead
SNP after Metabochip fine-mapping have substantially lower MAF and higher OR than the
previously reported GWAS lead SNP: PROX1 (rs17712208, MAF = 0.03, OR = 1.20;
rs340874, MAF = 0.48, OR = 1.06) and KLF14 (7-130116320, MAF = 0.02, OR = 1.10;
rs972283, MAF = 0.48, OR = 1.01). Since coverage across Metabochip fine-mapping
regions is incomplete, we cannot unequivocally exclude the presence of causal low-
frequency alleles at any single locus. However, the paucity of low-frequency candidate
alleles across 36 loci suggests that most causal variants at these loci are common. A
contribution of even rarer causal alleles (too rare to be represented on Metabochip) is also
unlikely because the substantial effect sizes required to drive common variant association
signals are inconsistent with the modest familial aggregation of T2D23. This interpretation,
favoring common causal alleles, is in agreement with the observed consistency of T2D risk
variant associations across major ancestry groups31.
Sex-differentiated analyses
We performed sex-differentiated meta-analysis32 (Online Methods and Supplementary Figs.
5 and 6) to test for association of each SNP with T2D, allowing for heterogeneity in allelic
effects between males (20,219 cases, 54,604 controls) and females (14,621 cases, 60,377
controls), thereby identifying two additional loci achieving genome-wide significance
(Table 2 and Supplementary Table 7). The association signal mapping near CCND2 is most
significant in males (male P = 1.1 × 10−9, female P = 0.036, heterogeneity P = 0.013), while
that upstream of GIPR is most significant in females (female P = 2.2 × 10−7, male P =
0.0037, heterogeneity P = 0.057) (Supplementary Fig. 7). The lead sex-differentiated SNP in
GIPR is only weakly correlated with previously reported associations with BMI15 (CEU r2 =
0.06) and two-hour glucose levels33 (CEU r2 = 0.07) (Supplementary Table 4).
The sex-differentiated analyses also revealed nominal evidence of heterogeneity (P < 0.05)
at four established T2D susceptibility loci (Table 2 and Supplementary Tables 7 and 8):
KCNQ1 (P = 0.0013), DGKB (P = 0.0068) and BCL11A (P = 0.012) were most
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significantly associated in males, and GRB14 (P = 0.0080) in females. The sex-
differentiated association at GRB14 is consistent with the female-specific effect on WHR
observed at this locus18. As KCNQ1 and DGKB demonstrate multiple independent
associations in the sex-combined meta-analysis, we investigated whether sex differences in
allelic effects were consistent across these signals (Supplementary Fig. 8). This appeared
true for DGKB (rs17168486, male P = 6.5 × 10−13, female P = 0.0052; rs6960043, male P =
7.9 × 10−7, female P = 0.015), but not KCNQ1 (rs163184, male P = 8.5 × 10−15, female P =
7.8 × 10−3; rs231361, male P = 2.9 × 10−6, female P = 2.9 × 10−6).
Understanding the biology of T2D susceptibility loci
For most T2D susceptibility loci, the underlying causal variants and the genes through
which they act are yet to be identified, and the pathophysiological processes mediating
disease risk remain unclear. We applied a variety of approaches to the newly discovered and
established T2D susceptibility loci, and in some cases to putative loci with more modest
evidence of association, to identify mechanisms involved in disease pathogenesis.
Physiological analyses
As noted earlier, lead SNPs at several newly identified loci are in strong LD with variants
associated with other T2D-related metabolic traits. To gain a more complete picture of
patterns of trait overlap, we first assessed the effect of T2D risk alleles on glycemic traits in
European-descent meta-analyses from the MAGIC Investigators (Online Methods). Fasting
glucose associations were analyzed for up to 133,010 non-diabetic individuals with GWAS
and/or Metabochip data34. In addition to the nine loci previously reported (MTNR1B,
DGKB, ADCY5, PROX1, GCK, GCKR, TCF7L2, SLC30A8 and C2CD4A)4,5, four more
T2D association signals were genome-wide significant for fasting glucose: CDKN2A/B (P =
5.7 × 10−18), ARAP1 (P = 1.2 × 10−10), IGF2BP2 (P = 1.8 × 10−8) and CDKAL1 (P = 2.0 ×
10−8) (Supplementary Table 9). The ZBED3 locus also attained genome-wide significance
with fasting glucose after adjustment for BMI (P = 1.2 × 10−8). In contrast, lead T2D SNPs
at 27 of the newly discovered and established loci showed no evidence of association with
fasting glucose (P > 0.05), despite sample sizes ranging from 38,424 to 132,999 individuals
(Supplementary Table 10 and Supplementary Fig. 9). Lead T2D SNPs at the remaining 24
loci were nominally associated with fasting glucose (P < 0.05), all with directionally
consistent effects. These data extend previous reports indicating that the genetic landscape
of pathological and physiological variation in glycemia is only partially overlapping, and are
consistent with reciprocal analyses reported in the companion MAGIC paper34.
Second, we extended our previous analysis4 of the physiological consequences of T2D risk
alleles to include the newly identified loci. We used the published MAGIC meta-analysis
(up to 37,037 non-diabetic individuals) of HOMA indices of beta-cell function and insulin
sensitivity5 as these traits were not included in the enlarged Metabochip study34. The risk
allele at ANK1 has features (nominally significant reduction in HOMA-B) indicating a
primary effect on beta-cell function, whereas those at GRB14 and AKNRD55 are
characteristic of loci acting primarily through insulin resistance (increased HOMA-IR)
(Supplementary Fig. 10 and Supplementary Table 10). The results for GRB14 are consistent
with its broad impact on insulin-resistance related traits (described below), while at
AKNRD55, these analyses point to MAP3K1, encoding MEK kinase, a key component of
the insulin-signalling pathway, as the stand-out local candidate.
Next, we examined the effect of T2D risk alleles on anthropometric and lipid traits using
data from the GIANT Consortium (up to 119,600 individuals after excluding data from T2D
case series)15 and the Global Lipids Genetics Consortium (up to 100,184 individuals)16
(Online Methods and Supplementary Tables 11 and 12). The only lead SNP to demonstrate
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convincing evidence of association (P < 10−5) with adiposity was at MC4R. The lead SNPs
at MC4R and GRB14 show the same pattern of lipid associations (P < 10−5): reduced HDL
and raised triglycerides. In contrast, the lipid associations at CILP2 and GIPR ran counter to
expected epidemiological correlations: T2D risk alleles were associated with reduced
triglyceride levels at both loci, and at CILP2 with reduced LDL and total cholesterol.
Finally, we noticed that the lead T2D SNP at the BCAR1 locus is genome-wide significant
for type 1 diabetes (T1D)35, although risk is conferred by the opposite alleles. Across 37
T1D susceptibility loci (Supplementary Fig. 11), we observed nominal evidence (P < 0.05)
of association to T2D at six. For three of these (BCAR1, GLIS3 and RAD51L1), the T1D
risk allele was protective for T2D, while at the others (C6orf173, COBL and C10orf59), the
effects were coincident. These data indicate that rates of diagnostic misclassification among
T2D cases in our study are low, and also highlight interesting points of overlap in the
processes involved in risk of, and protection from, these two major forms of diabetes.
Mapping potential causal transcripts and variants
The T2D-association signals emerging from the present meta-analysis map to regions
containing many transcripts and potential functional variants. To identify promising regional
transcripts, we examined expression quantitative trait locus (eQTL) data from a variety of
tissues (Online Methods and Supplementary Note). At six of the newly discovered loci, the
lead T2D SNP showed strong cis-eQTL associations and was highly correlated (CEU r2 >
0.8) with the lead cis-eQTL SNP (Supplementary Table 13). These “coincident” eQTL
implicate GRB14 (omental fat), ANK1 (omental and subcutaneous fat, liver and prefrontal
cortex), KLHDC5 (blood, T cells and CD4+ lymphocytes), BCAR1 (blood), ATP13A1 (at
the CILP2 locus, blood and monocytes), HMG20A (liver) and LINGO1 (also at the
HMG20A locus, adipose tissue). For those loci (GRB14, ANK1 and BCAR1) for which
individual-level expression data for the appropriate tissues were available36, we confirmed
signal coincidence by conditional analyses (Online Methods and Supplementary Table 14).
We used 1000 Genomes Project data13 to search for non-synonymous variants in strong LD
(CEU r2 > 0.8) with lead SNPs at the newly discovered loci (Online Methods). The only
candidate allele uncovered was a non-synonymous variant in exon 6 of TM6SF2
(19-19379549, CEU r2 = 0.98 with rs10401969) at the CILP2 locus. This change is
predicted by SIFT37 to have no appreciable effect on protein function.
Pathway and protein-protein interaction analyses
To extend previous efforts to define pathways and networks involved in T2D pathogenesis4,
we combined meta-analysis data with protein-protein interactions (PPI), semantic
relationships within the published literature and annotated pathways (Fig. 3). For these
analyses, we generated a “primary” list of 77 transcripts mapping nearest to lead SNPs at
T2D susceptibility loci or implicated in monogenic diabetes38 (Online Methods and
Supplementary Table 15).
Using a refined database of high-confidence PPI39,40, we constructed a network of 314
proteins from these 77 transcripts using DAPPLE41. We detected an excess of physical
interactions in the network, both direct (between the associated transcripts themselves, P <
10−4) and indirect (via 237 shared interactors not on the list of associated transcripts, P =
0.0070). There was no evidence that this set of shared interactors was enriched for T2D-
associated variants. Some interactions, such as those between the potassium channel
encoding genes KCNJ11 and ABCC8, are expected, while other sub-networks are of greater
novelty. For example, the transcriptional co-activator protein CREBBP, implicated in the
coupling of chromatin remodelling to transcription factor recognition, does not map to any
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T2D susceptibility locus. However, it is the most connected gene for protein-level
interactions (P < 0.005) in the PPI network, interacting with nine primary transcripts, eight
implicated in monogenic diabetes or mapping to established T2D susceptibility loci
(HNF1A, HNF1B, HNF4A, PLAGL1, TCF7L2, PPARG, PROX1 and NOTCH2) and one
from a locus with a strong, but not genome-wide significant, association (ETS1, lead SNP
rs7931302, P = 3.8 × 10−7). Other shared interactors identified through these analyses
included SERTAD1, FOXO1, PPARGC1A, GRB10 and MAFA. Several of these play roles
in the transcriptional regulation of diabetes-relevant tissues, and some also interact with
CREBBP. We used a pre-defined set of 1,814 genes encoding “DNA-binding proteins”
(Online Methods) to show that: (i) T2D signals are highly enriched for transcription factors
(21 of 71 primary transcripts listed within the HGNC catalog, compared to 1,793 of 19,162,
P = 2.3 × 10−6); and (ii) transcription factors within T2D loci are enriched for interaction
with CREBBP (taking the 1,164 listed in the protein interaction database, 9 of 21 compared
with 127 of 1,143, P = 2.7 × 10−4). These data suggest that modulation of CREBBP-binding
transcription factors plays an important role in T2D susceptibility.
The same set of 77 primary transcripts showed modest evidence of excess connectivity (P =
0.020 by permutation) using text-mining approaches42 (Online Methods). When we used
this set of 77 genes as a “seed” to query a list of 77 “secondary” transcripts (nearest to lead
SNPs with posterior probability of T2D-association >75% from the mixture model)
(Supplementary Table 15), we found significant connections (P < 0.001) between the
primary associated transcripts and four other genes: LEPR (leptin obesity pathways), MYC
(cell-cycle pathway), GATA6 (pancreas development pathway) and DLL4 (Notch signalling
target).
We also tested for enrichment of GWAS associated transcripts in pathway data. To retain
power, we focused on 16 biological hypotheses chosen for assumed relevance to T2D
pathogenesis4,43-45 (Supplementary Note). We used a two-step modified gene-set
enrichment analysis (GSEA) approach applied sequentially to Stage 1 (using MAGENTA46)
and Stage 2 meta-analyses (Online Methods and Supplementary Table 16). Of the 16
biological hypotheses tested, two demonstrated reproducible enrichment of T2D
associations. The strongest enrichment was observed for a broader set of primary and
secondary transcripts mapping to T2D-associated loci in the adipocytokine signalling
pathway (MAGENTA P = 6.2 × 10−5; modified GSEA P = 1.6 × 10−4). This gene set
includes the adiponectin, leptin and TNF-alpha signalling pathways previously implicated in
the development of insulin resistance47, but for which genome-wide significant common
variant associations with T2D susceptibility have not been previously reported. This analysis
highlighted eight genes in this pathway most likely to be causal for T2D susceptibility:
IRS1, LEPR, RELA, RXRG, ACSL1, NFKB1, CAMKK1 and a monogenic diabetes gene
AKT2. Members of this pathway were also strongly represented (17 out of 314) in the
DAPPLE PPI network (P = 7.5 × 10−14). Modest but robust enrichment was also observed
for genes influencing cell cycle, in particular regulators of the G1 phase during mitosis
(MAGENTA P = 2.0 × 10−4; modified GSEA P = 3.0 × 10−3). The majority of genes driving
these cell-cycle enrichments were cyclin-dependent kinase (CDK) inhibitors (CDKN2A/B,
CDKN1C and CDKN2C) and cyclins that activate CDKs (CCNE2, CCND2 and CCNA2).
Many of these regulate CDK4 or CDK6, which are known to play a role in pancreatic beta-
cell proliferation48,49. We saw no evidence of enrichment for other processes implicated in
T2D pathogenesis, including amyloid formation, ER stress and insulin signalling.
DISCUSSION
We have expanded T2D association analysis to almost 150,000 individuals. In so doing, we
have added another 10 loci to the list of confirmed common variant signals: for several of
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these, we have identified strong positional candidates based on expression data and known
biology. The data support the view that much of the overall variance in T2D susceptibility
can be attributed to the impact of a large number of common causal variants, most of very
modest effect. While such a model poses challenges for accumulating genome-wide
significant evidence of association at a specific variant, it does suggest that genetic profiling
based on the entirety of sequence variation has the potential to provide useful risk
stratification for T2D.
If common causal alleles explain a substantial component of T2D susceptibility, the
contribution of rare and low-frequency risk variants may be less than is often assumed: re-
sequencing studies will soon provide empirical data to address this question. In particular, it
will be important to determine whether, as the number of susceptibility loci increases, there
is evidence that the pathophysiological mechanisms implicated by human genetics coalesce
around a limited set of core pathways and networks. Our data suggest that this may be the
case, with a variety of analytical approaches pointing to cell cycle regulation, adipocytokine
signalling and CREBBP-related transcription factor activity as key processes involved in
T2D pathogenesis.
ONLINE METHODS
Stage 1 meta-analysis
The Stage 1 meta-analysis consisted of 12,171 T2D cases and 56,862 controls across 12
GWAS from European descent populations (Supplementary Table 1). Samples were typed
with a range of GWAS genotyping products. Sample and SNP quality control (QC) were
undertaken within each study. Each GWAS was then imputed at up to 2.5 million SNPs
using CEU samples from Phase II of the International HapMap Project28. Each SNP with
MAF >1% passing QC was tested for association with T2D under an additive model after
adjustment for study-specific covariates, including indicators of population structure. The
results of each GWAS were corrected for residual population structure using the genomic
control inflation factor50 and were combined via fixed-effects inverse-variance weighted
meta-analysis. The results of the Stage 1 meta-analysis were subsequently corrected by
genomic control (λGC = 1.10).
Stage 2 meta-analysis
The Stage 2 meta-analysis consisted of 21,491 T2D cases and 55,647 controls across 25
studies from European descent populations and 1,178 T2D cases and 2,472 controls from
one study of Pakistani descent (PROMIS) (Supplementary Table 1). All samples were
genotyped with Metabochip. Sample and SNP QC were undertaken within each study. Each
SNP with MAF >1% passing QC was tested for association with T2D under an additive
model after adjustment for study-specific covariates. We would expect inflation in
association signals across the content of Metabochip, even in the absence of population
structure, because it has been designed to be enriched for T2D and other T2D-related
metabolic trait loci. The results of each study were thus corrected for residual population
structure using the genomic control inflation factor obtained from a subset of 3,598
independent “QT-interval” SNPs (CEU r2 < 0.05), which were not expected to be associated
with T2D. The Stage 2 meta-analysis was performed in two steps: (i) combine all studies of
European descent; and (ii) add the PROMIS study. In both steps, the results of each study
were combined via fixed-effects inverse-variance weighted meta-analysis. The results of the
Stage 2 European meta-analysis were corrected by “QT-interval” genomic control (λQT =
1.19), but this adjustment was not then necessary after the addition of PROMIS (λQT = 0.99
was less than 1). Heterogeneity in allelic effects between European descent studies and
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subsequently between the European meta-analysis and PROMIS was assessed by means of
Cochran’s Q-statistic51.
Combined meta-analysis
The results of the Stage 1 and Stage 2 meta-analyses were combined for all Metabochip
SNPs via fixed-effects inverse-variance weighted meta-analysis. The combined meta-
analysis consisted of 34,840 cases and 114,981 controls. This was performed in two steps:
(i) combine Stage 1 meta-analysis with European descent Stage 2 meta-analysis; and (ii) add
the PROMIS study. The results of the combined European meta-analysis was corrected by
“QT-interval” genomic control (λQT = 1.13), but this adjustment was not necessary after the
addition of PROMIS (λQT = 0.98 was less than 1) (Supplementary Fig. 12). Heterogeneity
in allelic effects between the Stage 1 and Stage 2 meta-analyses was assessed by means of
Cochran’s Q-statistic.
Look-up of meta-analysis results for lead SNPs in GWAS of South and East Asian descent
We obtained summary statistics (RAFs, association P-values, allelic ORs and 95% CIs) for
lead SNPs at the newly discovered loci in meta-analyses of T2D GWAS in: (i) 5,561 cases
and 14,458 controls of South Asian descent10, excluding 1,958 overlapping samples from
PROMIS that were also included in our study, comprising 568,976 directly genotyped
autosomal SNPs; and (ii) 6,952 cases and 11,865 controls of East Asian descent11,
comprising 2,626,356 directly genotyped and imputed autosomal SNPs. For each SNP,
summary statistics were aligned to the risk allele in our primarily European descent meta-
analysis.
Calculation of sibling relative risk and liability-scale variance explained
Assuming a multiplicative model (within and between variants), the contribution to the
sibling relative risk of a set of N SNPs is given by
where pj and ψj denote the RAF and corresponding allelic OR at the jth SNP52. Assuming
disease prevalence, K, the liability-scale variance20 explained by these SNPs is given by
In this expression, T=φ−1(1-K), T1=φ−1(1-λSK), and ω=z/K, where z is the height of the
standard Gaussian density at T.
Z-score mixture modelling
We considered the distribution of Z-scores from the Stage 2 meta-analysis, aligned to the
risk allele from Stage 1, at a subset of 3,412 independent T2D replication variants (CEU r2 <
0.05), excluding lead SNPs and proxies (CEU r2 ≥ 0.1) at the 63 established and newly
discovered susceptibility loci on Metabochip. The Stage 2 Z-scores were modelled as a
mixture of two Gaussian distributions: (i) with mean zero and unit variance (i.e. under the
null hypothesis of no association); and (ii) with unknown mean (greater than zero) and
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variance (i.e. under the alternative hypothesis). The mean and variance of the alternative
distribution, and the mixing proportion, were estimated using an expectation-maximization
algorithm.
We estimated the posterior probability that each of the 3,412 independent replication SNPs
is truly associated with T2D from the mixture distribution. We approximated the
contribution of these SNPs to λS by simulation from the mixture distribution. For each
simulated replicate, we selected “causal” variants at random from these SNPs according to
their posterior probability of association. Over 1,000 replicates, we approximated the mean
and 95% CI for: (i) the number of “causal” variants among the 3,412 independent replication
SNPs; and (ii) the contribution to λS, using estimated RAFs and allelic ORs from the Stage
2 meta-analysis. For each replicate, we also generated a hypothetical third stage to the study
consisting of 100,000 T2D cases and 100,000 controls. For each “causal” variant, we
generated association summary statistics (Z-score aligned to the risk allele from Stage 1)
according to the RAF and allelic OR from our Stage 2 meta-analysis.
Assessment of allele frequency variation across European populations
We calculated F-statistics (FST) across European populations using data from the 1000
Genomes Project (CEU, TSI, FIN, GBR and IBS)13 for the subset of SNPs selected for
replication on Metabochip. FST was calculated by comparing mean heterozygosity across all
populations to the mean within each sub-population, weighted by the number of contributing
chromosomes from each sub-population. We compared FST for the subset of T2D
replication SNPs that were directionally consistent between Stage 1 and Stage 2 meta-
analyses with all Metabochip replication SNPs (up to 65,345 SNPs), using the Kolmogorov-
Smirnov test.
False-discovery rate (FDR) analysis
We undertook FDR analysis53 of 64,646 Metabochip replication SNPs using combined
meta-analysis P-values. From this analysis, we observed , consistent with an excess
of true positives in this set. We compared these P-values with FDR Q-values and posterior
probabilities of membership to the alternative distribution from the mixture model
(Supplementary Fig. 4) at the set of 2,172 T2D replication SNPs with concordant direct of
allelic effect in both stages of the meta-analysis, after exclusion of 11 AT/GC SNPs with
obvious strand orientation misalignments. FDR analysis also indicated an excess of expected
true positives in this set of SNPs, even at relatively consistent thresholds (for example, we
expect one false positive and 66 true positives at a Q-value of 0.014).
Sex-differentiated meta-analysis
The Stage 1, Stage 2 and combined meta-analyses described above were repeated for males
and females separately with correction for population structure within each sex
(Supplementary Fig. 13). The male-specific meta-analysis consisted of 20,219 cases and
54,604 controls, while the female-specific meta-analysis consisted of 14,621 cases and
60,377 controls. The sex-specific meta-analyses were then combined to conduct a sex-
differentiated test of association and a test of heterogeneity in allelic effects between males
and females32.
Physiological analyses
We obtained summary statistics (association P-values and Z-scores for direction of effect or
allelic effects and standard errors) for lead T2D SNPs in GWAS meta-analyses of metabolic
traits in European descent populations. Summary statistics were aligned to the T2D risk
allele from the combined meta-analysis. We obtained summary statistics for lead SNPs in all
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newly discovered and established loci for glycemic traits in non-diabetic individuals from
the MAGIC Investigators5,34. For fasting glucose and fasting insulin, the meta-analysis
comprised up to 133,010 individuals, genotyped with GWAS arrays and imputed on up to
~2.5 million SNPs, or genotyped with Metabochip. We also considered surrogate estimates
of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) derived by homeostasis
model assessment in up to 38,238 individuals (from GWAS meta-analysis only since these
traits were not investigated in the enlarged MAGIC Metabochip study). We obtained
summary statistics for lead SNPs in the newly discovered T2D loci (also including GRB14
and HMG20A) for BMI in up to 119,600 individuals from the GIANT Consortium15. To
eliminate potential bias in BMI allelic effect estimates at T2D susceptibility loci54, we
restricted our attention to meta-analysis of population-based studies not ascertained for
disease status for ~2.8 million directly genotyped and/or imputed SNPs. We obtained
summary statistics for the same SNPs for plasma lipid concentrations from the Global Lipids
Genetics Consortium16. This meta-analysis comprised ~2.6 million directly genotyped and/
or imputed SNPs assessed for association to plasma concentrations of: total cholesterol (up
to 100,184 individuals); LDL (up to 95,454 individuals); HDL (up to 99,900 individuals);
and triglycerides (up to 96,598 individuals).
We also examined T2D association summary statistics at lead SNPs for 37 established T1D
susceptibility loci. For each of these SNPs, we reported the allelic OR (aligned to the T2D
risk-allele) and P-values in: (i) our Stage 1 T2D meta-analysis; and (ii) a GWAS meta-
analysis of 7,514 T1D cases and 9,045 population controls from European descent
populations from the Type 1 Diabetes Genetics Consortium35.
Expression analyses
We identified proxies (CEU r2 > 0.8) for each lead T2D SNP in our newly discovered loci
(also including GRB14 and HMG20A). We interrogated public databases and unpublished
resources for cis-eQTL expression with these SNPs in multiple tissues (details of these
resources are summarized in the Supplementary Note). The collated results from these
resources met study-specific criteria for statistical significance for association with transcript
expression. For each transcript associated with a lead T2D SNP (or proxy), we identified the
lead cis-eQTL SNP, and then estimated LD between them using 1000 Genomes Project data
to assess coincidence of the signals.
We subsequently tested for association of each lead T2D SNP with the expression of
flanking transcripts (within a 1 Mb window) in 603 subcutaneous adipose tissue samples and
745 peripheral blood samples from individuals from the Icelandic population, genotyped
using the Illumina HumanHap 300 Bead Array, and imputed up to ~2.5M SNPs36. We
modelled the log-average expression ratio of two fluorphores as a function of the allele
count (expected allele count for imputed SNPs) in a linear regression framework, with
adjustment for age and sex (and differential cell count for blood samples) as covariates. All
P-values were also adjusted for the relatedness between individuals by simulating genotypes
through the corresponding Icelandic genealogy55. We also identified the most strongly
associated cis-eQTL SNP for each flanking transcript. We then performed a conditional test
of association of the transcript with the cis-eQTL SNP within the same linear regression
framework, with additional adjustment for the lead T2D SNP as a covariate. The conditional
analyses determine whether the cis-eQTL SNP association with the transcript can be
explained by the lead T2D SNP.
We searched the 1000 Genomes Project data (Phase I interim release) for non-synonymous
variants in strong LD (CEU r2 > 0.8) with lead T2D SNPs in the newly discovered loci (also
including GRB14 and HMG20A). Identified non-synonymous variants were subsequently
interrogated for likely downstream functional consequences using SIFT37.
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Pathway, text mining and PPI analyses
We generated two lists of transcripts on the basis of the results of the sex-combined and sex-
differentiated meta-analyses. The “primary” list included: (i) the nearest transcript to the
lead SNP at 41 previously reported common variant loci identified in European descent
populations; (ii) the nearest transcript to the lead SNP at the ten newly identified loci (P < 5
× 10−8) from the sex-combined meta-analysis, including GRB14 and HMG20A; (iii) the
nearest transcript to the lead SNP at both novel signals (P < 5 × 10−8) from the sex-
differentiated meta-analysis; (iv) the nearest transcript to the lead SNP at six additional loci
with the strongest evidence of association (P < 5 × 10−7) from the sex-combined meta-
analysis; and (v) 18 genes implicated in monogenic forms of diabetes38, not already
overlapping other loci included in the list. The “secondary” list incorporated the nearest
transcript to the lead SNP at 77 additional loci with posterior probability of association of at
least 75% from the mixture model, not already included in the primary list.
We tested the hypothesis that a PPI network built from the 77 primary transcripts was
significantly enriched for physical interaction over and above that expected by chance using
DAPPLE41. To build networks, DAPPLE uses a refined database of high-confidence
interactions39,40, which emphasizes confidence of interaction over completeness, with the
result that not all proteins are represented. We considered two categories of interactions:
direct (i.e. between the associated transcripts themselves) and indirect (i.e. via common
interactors that were not among the associated transcripts). We assessed the significance of
the enrichment of physical interactions by permutation. Subsequently, we used the network
as a “seeds” to query against the 77 secondary transcripts.
We used GRAIL to highlight genes from T2D susceptibility loci using similarity of text in
PubMed abstracts or in gene-ontology associated codes42. To reduce confounding by
published T2D GWAS analyses, we restricted our analysis to abstracts published prior to
December 2006. We first tested for enrichment of connectivity in the list of 77 primary
transcripts (treating the 18 monogenic loci as a single locus to reduce confounding), and
assessed significance via permutation4. These gene sets were then used as the “seed” against
which the list of 77 secondary transcripts was queried for connectivity.
We employed a two-step GSEA strategy to test for enrichment of transcripts in T2D
susceptibility loci within pathways pertaining to 16 biological hypotheses related to disease
pathogenesis (full details of these hypotheses are presented in the Supplementary Note). In
the first step, we applied MAGENTA46 to the Stage 1 meta-analysis. Genes in each pathway
were scored on the basis of the most significant “local” SNP association using -110 kb/+40
kb boundaries. The 95th percentile of association P-values from all genes in the genome was
used to determine the enrichment cut-off. In the second “replication” step, nominally
significant gene sets from step one (MAGENTA P < 0.05) were tested for enrichment of
T2D association signals in the Stage 2 meta-analysis. To account for the bias in the
Metabochip design to SNPs nominally associated with T2D and related metabolic traits, we
employed a modified GSEA approach. We tested for enrichment among a broader set of
primary or primary and secondary transcripts within LD regions defined by r2 > 0.5 on
either side of the lead SNP, extended to the nearest recombination hotspot and then an
additional 50 kb (if there was no gene within the LD region, we used the nearest transcript).
For robustness testing, we also examined enrichment in the nearest gene to the lead SNPs.
The modified GSEA P-value was computed as the fraction of randomly sampled sets of loci,
matched for number and local gene density to our primary and secondary lists, which have
the same or more significant hyper-geometric probability than that of the T2D loci. For the
“null” set, we used 1,600 LD-pruned Metabochip T2D replication SNPs with the lowest
posterior probability of association (<5%) from the mixture model. To control for potential
confounders, we applied the modified GSEA approach to two negative control lists: (i) loci
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defined by the lowest ranked independent T2D replication SNPs from our Stage 2 meta-
analysis; and (ii) loci for QT-interval on the basis of our Stage 2 meta-analysis for
independent replication SNPs for this trait, excluding those within our primary and
secondary lists of T2D susceptibility loci and those near monogenic diabetes genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Distribution of Z-scores from the Stage 2 meta-analysis, aligned to the risk allele from Stage
1. Z-scores were calculated at a subset of 3,412 independent T2D replication SNPs (CEU r2
< 0.05), excluding the 63 established and newly discovered autosomal susceptibility loci
represented on Metabochip. The Z-score distribution is a mixture of: (i) the “null
distribution” of SNPs having no effect on T2D (blue curve); and (ii) the “alternative
distribution” of SNPs associated with the disease (red curve).
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Figure 2.
Regional plots of T2D susceptibility loci with evidence of multiple association signals. Each
point represents a Metabochip SNP passing quality control in our combined meta-analysis,
plotted with their P-value (on a -log10 scale) as a function of genomic position (NCBI Build
36). In each panel, the lead SNP is represented by the purple diamond. The color coding of
all other SNPs (circles) indicates LD with the lead SNP (estimated by CEU r2 from the 1000
Genomes Project June 2010 release): red r2 ≥ 0.8; gold 0.6 ≤ r2 < 0.8; green 0.4 ≤ r2 < 0.6;
cyan 0.2 ≤ r2 < 0.4; blue r2 < 0.2; grey r2 unknown. Recombination rates are estimated from
the International HapMap Project and gene annotations are taken from the University of
California Santa Cruz genome browser.
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Figure 3.
Functional analyses. (a,b) Protein-protein interaction (PPI) sub-network for CREBBP and
adipocytokine interactions. All direct interactions and common interactors between direct
connections were extracted from the larger network of 314 proteins defined in the DAPPLE
network analysis. Genes in the network are circles (nodes), colored according to the
statistical relationship with T2D: common interactors between GWAS identified or
monogenic loci are depicted as grey, monogenic loci (only) in blue, GWAS identified loci
(only) in red, and loci with GWAS association and implicated by monogenic forms of
diabetes are shown in green. Each interaction defined in the inWEB network is depicted by a
line (edge) between nodes. (c) GRAIL circle plot of locus connectivity. Each locus is plotted
in a circle where significant connections (P < 0.05) based on PubMed abstracts are drawn
spanning the circle. Conservatively, we treated all monogenic loci (region 142) as a single
locus by which connectivity is assessed. The strongest connections (P < 0.001) are colored
in bright red. (d) GSEA of associations in the adipocytokine signaling pathway. The black
bars represent the Stage 1 meta-analysis P-values of 63 autosomal genes in the
Adipocytokine Signaling pathways (KEGG). A density plot of the black bars is depicted in
the top panel (red line). The replicating genes in the leading edge of the GSEA are listed.
The Stage 2 modified GSEA P = 1.6×10−4 was calculated based on both the primary and
secondary transcripts using the LD locus definition.
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